ProSomnus® Sleep Technologies Announces Signing of Definitive Agreements for $30 Million of Convertible Notes

Financing will support Company's pending business combination and fund strategic growth initiatives SAN FRANCISCO, Aug. 26, 2022 /PRNewswire/ -- ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA),...

Click to view original post